Leadership expansion reinforces ELRIG's commitment to delivering impactful drug discovery initiatives and driving community-wide collaboration
We recently hosted our Ask the Experts Live Q&A: From Preclinical to First-in-Human.
In this session, our experts explored the strategic decisions that shape early clinical success, covering key considerations for transitioning from preclinical development into first-in-human studies. Drawing on their extensive experience, they discussed common challenges, practical approaches to reducing development risk, and the critical decisions that can help keep programmes on track.
About AstraZeneca
AstraZeneca is a global, science-led, patient-focused biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines for some of the world’s most serious diseases. But we’re more than one of the world’s leading pharmaceutical companies. At AstraZeneca, we are pioneering new frontiers by identifying and treating patients earlier, working towards the aim of eliminating cancer as a cause of death.
Plurify is an early-stage, fast-moving biotech building platform technologies to help unlock the next generation of stem cell and gene therapies. Our work targets the most stubborn manufacturing bottlenecks - including the unwanted residual cells and plasmids left behind during cell and gene therapy production - with scalable, precisely targeted solutions. With several Innovate UK grants and strong private backing behind us, we're growing the team.
💡 THE OPPORTUNITY
By Philippa Clark, Director of Business Development, One Nucleus
Company Description
TTP is an employee-owned technology and product development consultancy, with a 40-year track record of partnering with ambitious clients to solve complex challenges and bring innovative, commercially successful solutions to market.
We invent, design, and manufacture impactful products and technologies across a wide range of industries – including healthcare, life science, energy, and communications – and at the intersection of engineering, physical science, and biology.
Join us at the world-leading CRUK Cambridge Institute. We're a unique department of the University of Cambridge, core funded by Cancer Reserch UK's charitable activities, and we're eagerly searching for a Research Data Manager to join our IT and Scientific Computing team.
We’re looking for a Deputy Pharmaceutical Production Manager for the new Faecal Microbiota Transplant (FMT) Facility at the Quadram Institute.
We are seeking to appoint a Deputy Pharmaceutical Production Manager with an interest in human studies to investigate the application of Faecal Microbiota Transplant (FMT) for the treatment of gastrointestinal disorders and other microbiome associated diseases to join the existing FMT Team.
Pioneer Group, a specialist life science infrastructure and venture building business, and Firoka, a hospitality and real estate group, have secured unanimous resolution to grant planning permission for the transformation of Ozone Leisure Park in Oxford.
The decision marks a major milestone for Ozone Oxford, a new mixed-use campus that will bring together research, workspace, leisure and community facilities on the existing Ozone Leisure Park site.
As the UK’s leading dementia research charity, we’re determined to stop this from becoming a reality. We’re working to revolutionise the way we treat, diagnose and prevent dementia. But we will not stop there. With your support, we will keep going until every person is free from the heartbreak of dementia. We exist for a cure.